News | 04 January 2022
Combination of Covishield-Covaxin more effective: AIG hospital study
The first pilot study from India analyzing Covaxin-Covishield mixed doses
The first pilot study from India analyzing Covaxin-Covishield mixed doses
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Aim of the virtual conference is to facilitate Indian Pharma Industry adopt Green & Sustainable Chemistry as a tool to enhance Economic & Environmental Competitiveness
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
The facility at the Andhra Pradesh Medtech Zone is expected to be completed by Dec 2022
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Flattish volume growth and subdued new launches were key factors for last month
The single-dose vaccine has been approved in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination
The company has started manufacturing the Sputnik Light vaccine
Sputnik Light as a booster significantly increases virus-neutralizing activity against Omicron based on sera 2-3 months after revaccination and is a universal booster to other vaccines inducing stronger antibody and T-cell response
Subscribe To Our Newsletter & Stay Updated
